Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Small Study Of Novartis Asthma Drug Shows Promising Results

XTALKS VITALS NEWS

Asthma

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs.

Tweetables from this article:

Tweet: #Asthma drug could lower inflammatory #biomarkers more effectively when compared to the placebo http://ctt.ec/c_o6b+Asthma drug could lower inflammatory biomarkers more effectively when compared to the placebo.

Tweet: By the year 2020, the US market for #asthma drugs is expected to reach $14 billion http://ctt.ec/P0dpl+By the year 2020, the US market for asthma drugs is expected to reach $14 billion.

Share this!

August 9, 2016 | by Sarah Massey, M.Sc.

An experimental asthma medication developed by Novartis has shown promising results in a recent small investigational study. The results – which were published in the journal, The Lancet Respiratory Medicine – suggest that the drug could lower inflammatory biomarkers more effectively when compared to the placebo.

The trial involved 61 patients who were randomly assigned to receive the experimental drug, called fevipiprant, or a placebo. The drug is a prostaglandin D2 receptor 2 antagonist, and was successful at significantly reducing the eosinophil count in those with moderate to severe asthma.

The oral drug is a departure from traditional asthma inhalers, in which the medication is delivered directly into the lungs. According to Reuters, the Swiss drugmaker hopes to file for regulatory approval in 2019.



To meet that goal, Novartis will need to conduct further studies involving more patients in order to prove the efficacy of fevipiprant. If approved, the drug could be the first new oral treatment for asthma since the 1950s.

By the year 2020, the US market for asthma drugs is expected to reach $14 billion, according to GBI Research. In 2013, the market was worth $11.7 billion.

While pharma giants GlaxoSmithKline, Merck and AstraZeneca are all major players in the asthma space, Novartis is hoping to gain market share with fevipiprant. As much of the R&D into new asthma therapies has focused on inhaled drugs, most of the top-selling medications for the respiratory condition utilize that form of drug delivery.

The current study was conducted at Glenfield Hospital in Leicester, UK. Fevipiprant was described as having a good safety profile, with no serious adverse events reported.


Keywords: Asthma, Biomarker, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.